Загрузка...
Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity
Discrepancies between HIV-1 RNA results assayed by different FDA-approved platforms have been reported. Plasma samples collected from 332 randomly selected clinical trial participants during the second year of antiretroviral treatment were assayed with three FDA-approved platforms: UltraSensitive Ro...
Сохранить в:
| Опубликовано в: : | J Clin Microbiol |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Microbiology
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4508432/ https://ncbi.nlm.nih.gov/pubmed/26063861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JCM.00801-15 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|